Skip to content

Effects of Piracetam and Rivastigmine on Alzheimer's disease

Piracetam, Rivastigmine and their joint consumption effects on Mini Mental Status Examination in patients with Alzheimer's disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201112198430N2
Enrollment
64
Registered
2012-05-11
Start date
2009-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer. Dementia in Alzheimer's disease

Interventions

Intervention 1: First group of intervention: Exelon, Capsule 1.5 mg oral, once daily for 3 months. Intervention 2: Control group: placebo, capsule oral, once daily for 3 months. Intervention 3: Second
Treatment - Drugs
Placebo
First group of intervention: Exelon, Capsule 1.5 mg oral, once daily for 3 months.
Control group: placebo, capsule oral, once daily for 3 months.
Second group of intervention: Piracetam, capsule 800 mg oral, once daily for 3 months.
Third group of intervention: Exelon, Capsule1.5 mg oral, once daily for 3 months and Piracetam, capsule 800 mg oral, once daily for 3 months.

Sponsors

Vice chancellor for research of Rafsanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- age more than 40; 2- diagnosis of Alzheimer disease based on DSM-IV criteria. Exclusion criteria: 1- history of consuming drugs (except for drugs used for controlling hypertension, heart ischemia, hyperlipidemia, diabetes); 2- history of other diseases; 3-Allergy to Piracetam or Rivastigmine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mini Mental Status Examination. Timepoint: beforthe intervention and 3 months after intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farhad Iranmanesh

Kerman University of Medical Sciences

fpp_farhad@yahoo.com00893412467139

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026